At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,475 enrolled
Drug / intervention
Vitamin D3dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19
In Brief
A clinical study evaluating Vitamin D3 for SARS-CoV-2 Infection. Completed, enrolled 1,475 participants across 2 sites.
Detailed Summary
The purpose of this study is to compare the risks of COVID-19 in individuals from Chicagoland communities randomized to low (400 IU/day) vs. moderate (4,000 IU/day) or high (10,000 IU/day) dose vitamin D.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2 Infection
CountriesUnited States
CollaboratorsRush University Medical Center
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartNov 2020
First PostedMay 2021
Primary CompletionDec 2024
TodayJul 2026
First PostedMay 3, 2021
Enrollment StartNov 30, 2020
Primary CompletionDec 1, 2024
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 5.2 years ago
Interventions
Vitamin D3dietary
Half the subjects will be randomized to the low dose vitamin D therapy (400 IU/day), which will serve as the control group, and half to moderate (4,000 IU/day) or high (10,000 IU/day). Study participants will have the option between being randomized to the low versus moderate or the low versus high dose arms.